Table 3 RE-AIM measures
Implementation outcome | Measurement strategy | Data collection methodology |
|---|---|---|
Reach | Reach of the site-specific HCV treatment workflows: the proportion of study participants who are offered HCV treatment (Offered HCV treatment will be measured by the presence of a prescription for an HCV medication in the EMR) | Primary data collection EMR chart review |
Effectiveness | Primary outcome: the proportion of study participants that achieve SVR12 Secondary outcomes: the proportion of study participants that complete treatment. The proportion of study participants that initiate treatment | Primary data collection |
Adoption | The proportion of providers who are trained per site | Primary data collection |
Implementation | The extent to which the site-specific HCV treatment workflows are implemented as intended (fidelity) for study participants Markers include the following: the proportion of study participants who were genotyped, among study participants who reached SVR12. The proportion of study participants for whom an ultrasound was ordered, among non-cirrhotic study participants who reached SVR12 | EMR chart review and qualitative interviews with clinic staff |
Maintenance | The extent to which the site-specific HCV treatment workflows are sustained over the study’s 16-month data collection period | EMR chart review and qualitative interviews with clinic staff |